Health
Nona Biosciences and INGENIA Therapeutics Enter into Collaboration Agreement
CAMBRIDGE, Mass., Oct. 13, 2023 /PRNewswire/ -- Nona Biosciences, a global pioneer of technology innovation and antibody discovery and development solutions, and INGENIA Therapeutics, a preclinical-stage biotech company with a breakthrough technology to restore defective blood vessels, announced ...
2023-10-13 23:26
2356
Offering broader access to sustainable and scalable pharma-grade saponin adjuvants
SPI Pharma, Inc. and Q-Vant Biosciences, Inc. announce a strategic partnership which includes an investment to expand Q-Vant's proprietary 100% sustainable Q-SAP™ technology, and the signing of an exclusive commercial agreement to accelerate global adoption of their high-purity saponin adjuvants ...
2023-10-13 21:47
2510
Inmagene Doses First Patient in Phase 2a Trial of IMG-007, an Anti-OX40 Monoclonal Antibody with an Extended Half-life, for the Treatment of Alopecia Areata
* IMG-007 is a novel anti-OX40 monoclonal antibody (mAb) engineered for potentially once every 12 weeks dosing and an improved safety profile * IMG-007 is being evaluated for the treatment of alopecia areata (AA) and atopic dermatitis (AD) * An interim data readout in AA is expected in Q3 20...
2023-10-13 20:00
1346
Actinogen to present progress on Phase 2 trials at the BIO Investor Forum, San Francisco and Clinical Trials on Alzheimer's Disease (CTAD) Conference, Boston
Xanamem® is an oral, brain-penetrant tissue cortisol synthesis inhibitor that has shown promising safety and clinical activity in three placebo-controlled trials and has the potential to treat a variety of neurodegenerative and neuropsychiatric diseases SYDNEY, Oct. 13, 2023 /PRNewswire/ -- Acti...
2023-10-13 20:00
2005
World Thrombosis Day encourages public to "Move Against Thrombosis" to celebrate 10 years of raising awareness worldwide
CHAPEL HILL, N.C., Oct. 13, 2023 /PRNewswire/ -- Today is World Thrombosis Day, a global effort by the International Society on Thrombosis and Haemostasis (ISTH) to spread awareness of the signs, symptoms and risk factors of thrombosis, commonly known as blood clots. World Thrombosis Day engages...
2023-10-13 15:00
526
Hilton Properties in Malaysia Invites All To Sip, Savor and Support This Pinktober
Breast cancer awareness takes center stage as Hilton properties in Malaysia unveils pinktober celebration through the lens of mindful eating KUALA LUMPUR, Malaysia, Oct. 13, 2023 /PRNewswire/ -- Hilton properties across Malaysia, including Hilton Kuala Lumpur, DoubleTree by Hilton Putrajaya Lakes...
2023-10-13 13:30
2332
GenScript ProBio Congratulates ABL Bio's IND Clearance of ABL103 Program from MFDS
SEOUL, South Korea, Oct. 13, 2023 /PRNewswire/ -- Recently, ABL Bio, a partner of GenScript ProBio, announced the Ministry of Food and Drug Safety (MFDS) cleared of its clinical trial application for innovative bispecific antibody program (B7H4x4-1BB) in solid tumor. GenScript ProBio warmly exten...
2023-10-13 09:00
1864
SK Biopharmaceuticals' Proteovant Therapeutics Presents Preclinical Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
New data presented on novel orally bioavailable p300-selective degraders showing significant anti-tumor activity in preclinical models of androgen receptor (AR) positive prostate cancer SEOUL, South Korea and KING OF PRUSSIA, Pa., Oct. 12, 2023 /PRNewswire/ -- SK Biopharmaceuticals, a global bio...
2023-10-13 09:00
1321
Global Registrational Phase III Study of Bcl-2 Inhibitor Lisaftoclax in Treatment-Naïve Patients with CLL/SLL Approved by the China CDE
ROCKVILLE, Md. and SUZHOU, China, Oct. 12, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that the Center for Drug Evaluation (CDE) of China ...
2023-10-13 08:22
1392
Specialised Therapeutics signs exclusive license agreement with CanariaBio for new ovarian cancer therapy
.. First ovarian cancer therapy for ST oncology portfolio .. Phase 2 study demonstrated oregovomab in combination with chemotherapy improved progression free survival by ~30 months compared to chemotherapy alone1 .. Phase 3 results expected in 2025 .. Exclusive license for AU, NZ, Singapore, Mal...
2023-10-13 03:00
1822
M42 Announces New Clinical LLM to Transform the Future of AI in Healthcare
ABU DHABI, UAE, Oct. 13, 2023 /PRNewswire/ -- M42, a global tech-enabled healthcare network, has unveiled an impactful advancement in healthcare technology with the launch of Med42, a new open-access Clinical Large Language Model (LLM). The 70 billion parameter, generative artificial intelligence...
2023-10-13 01:26
1964
Discovery Life Sciences Announces Major Strategic Expansions: New State-of-the-Art Facilities, Advanced Technologies, and Global Brand Enhancements
HUNTSVILLE, Ala., Oct. 12, 2023 /PRNewswire/ -- Discovery Life Sciences (Discovery), the Biospecimen and Biomarker Specialists, has moved to its new global headquarters at the HudsonAlpha Institute of Biotechnology campus in Huntsville, Alabama. Alongside this relocation, the company's AllCells ce...
2023-10-12 22:00
1655
CARsgen's CAR-GPC3 T-cell Therapy for Advanced Hepatocellular Carcinoma: Two Patients Achieved over 7 Years of Disease-free Survival
SHANGHAI, Oct. 12, 2023 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announced the publication of two cases of long-term disease-free survival in th...
2023-10-12 20:50
1396
Akeso Announced The Lancet Oncology Publishes Promising Clinical Results from Cadonilimab in Patients with Advanced Solid Tumours (COMPASSION-03/AK104-201)
HONG KONG, Oct. 12, 2023 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso") announced that the results of the multicenter, open-label Phase Ib/II clinical trial (COMPASSION-03/AK104-201) for cadonilimab (PD-1/CTLA-4 bispecific antibody), the globally first bispecific IO drug used to treat advanced s...
2023-10-12 20:00
1220
Phabuilder Presents "Phamily" at the Go!PHA Congress: A New Era for PHA Materials
ATLANTA, Oct. 12, 2023 /PRNewswire/ -- During the 3rd PHA World Congress organized by Go!PHA, Phabuilder introduced its Phamily brand initiative, which focuses on diverse and high-end PHA materials research, aiming to provide comprehensive product resources and supporting technical services to gl...
2023-10-12 20:00
1196
Emulate Earns Frost & Sullivan's 2023 Technology Innovation Leadership Award
Cutting-edge Organ-on-a-Chip Technology Enhances R&D Productivity and Improves Patient Safety SAN ANTONIO, Oct. 12, 2023 /PRNewswire/ -- Frost & Sullivan recently researched the North American Organ-on-a-Chip industry and, based on its findings, recognizesEmulate with the 2023 Technology Innovat...
2023-10-12 20:00
1354
Metabolon Launches New Liver Fibrosis and Kidney Function Discovery Panels to Reveal Disease Mechanisms and Facilitate Research
Metabolon's newest panels help academic and commercial researchers reveal complex biological insights about liver fibrosis and kidney dysfunction MORRISVILLE, N.C., Oct. 12, 2023 /PRNewswire/ -- Metabolon, Inc., the global leader in providing metabolomics solutions advancing a wide variety of lif...
2023-10-12 19:57
1300
HanAll Biopharma, Daewoong Pharmaceutical and NurrOn Pharmaceuticals Initiate First-in-Human Phase 1 Clinical Study of HL192
* HanAll Biopharma and Daewoong Pharmaceutical marked a pivotal step forward in the development of HL192 (ATH-399A) for the potential treatment of Parkinson's Disease in collaboration with NurrOn Pharmaceuticals. * The Phase 1 Study evaluates the safety, tolerability, and pharmacokinetics of ...
2023-10-12 19:00
1183
MediLink Therapeutics Announces Strategic Collaboration and Worldwide License Agreement with BioNTech to develop next-generation anti-cancer antibody-drug conjugate
SUZHOU, China, Oct. 12, 2023 /PRNewswire/ -- MediLink Therapeutics ("MediLink"), announced today that it has entered into a strategic research collaboration and worldwide license agreement with BioNTech SE (Nasdaq: BNTX, "BioNTech"), a next generation immunotherapy company pioneering novel therap...
2023-10-12 19:00
1362
Scott's and 99Speedmart Join Forces to Launch Donation Campaign to Serve Underprivileged Children's Nutritional Needs
* One-month BUY1DONATE1 campaign to be rolled out nationwide, enabling anyone to take part in giving back * Donations of Scott's products to supplement the nutritional needs of 5,000 underprivileged children KUALA LUMPUR, Malaysia, Oct. 12, 2023 /PRNewswire/ -- Scott's, the market leader in t...
2023-10-12 18:56
1667
Week's Top Stories
Most Reposted
Earth Day 2024: Angel Yeast Continues to Tackle Plastic Pollution Challenges With Bio-based Material Solutions
[Picked up by 294 media titles]
2024-04-22 16:00
Trina Solar and PetroGreen Partner to Accelerate Philippine Solar Adoption with 117MW Supply Agreement
[Picked up by 291 media titles]
2024-04-22 06:00
Revenue Surpasses 50 Billion: BlueFocus Accelerates Towards the AI Native Era
[Picked up by 275 media titles]
2024-04-23 15:43
INTAMSYS Becomes 3D Printing Equipment Supplier for the WORLDSKILLS LYON 2024 COMPETITION
[Picked up by 273 media titles]
2024-04-24 17:09
Introducing Wacom Movink: The first OLED pen display, and the thinnest and lightest Wacom pen display ever
[Picked up by 268 media titles]
2024-04-24 13:00
Most Read
Automation Anywhere Appoints Tim McDonough as Chief Marketing Officer to Drive Global Awareness and Growth for the Leader in AI-Powered Automation
2024-04-24 03:57
6686
Earth Day 2024: Angel Yeast Continues to Tackle Plastic Pollution Challenges With Bio-based Material Solutions
2024-04-22 16:00
4462
Trina Solar and PetroGreen Partner to Accelerate Philippine Solar Adoption with 117MW Supply Agreement
2024-04-22 06:00
4057
INTAMSYS Becomes 3D Printing Equipment Supplier for the WORLDSKILLS LYON 2024 COMPETITION
2024-04-24 17:09
3812
Revenue Surpasses 50 Billion: BlueFocus Accelerates Towards the AI Native Era
2024-04-23 15:43
3700